Emile Voest

Emile Voest

More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.

Back to news

More news

Single WGS analysis of metastases is sufficient in most cases

Single WGS analysis of metastases is sufficient in most cases

26-10-2021

DNA analysis of the tumor is of crucial importance to determine treatment options for patients with metastasized lung cancer. But …

In the media: Genomeweb: Partial reimbursement for comprehensive DNA test in the Netherlands

In the media: Genomeweb: Partial reimbursement for comprehensive DNA test in the Netherlands

09-04-2021

This week, Genomeweb’s Precision Oncology News brought the news that the Dutch House of Representatives has recently unanimously decided to …

New CPoC grant awarded: GLOW – GLioblastoma targeted treatment Option maximisation by WGS

New CPoC grant awarded: GLOW – GLioblastoma targeted treatment Option maximisation by WGS

27-05-2021

Oncode Institute has announced that the 13th grant within the Clinical Proof of Concept programme has been awarded. Oncode Investigator …

Would you like to be kept up to date with new developments?

Sign up for our newsletters

Want to know more about the complete DNA test?

Visit OncoAct.nl